U.S. Electronic Equipment and Components Stock News

NasdaqCM:LCNB
NasdaqCM:LCNBBanks

LCNB (LCNB) Net Margin Jump To 25.5% Tests Long Term Caution Narrative

LCNB (LCNB) closed out FY 2025 with fourth quarter revenue of US$22.3 million and basic EPS of US$0.40, while trailing twelve month figures showed revenue of US$90.1 million and EPS of US$1.63 as the bank reported net income of US$23.0 million over the period. Over recent reporting periods, revenue has moved from US$79.2 million and EPS of US$0.97 on a trailing basis at the end of 2024 to US$90.1 million and EPS of US$1.63 by the end of 2025, highlighting a period where net margins and...
NasdaqGM:GAMB
NasdaqGM:GAMBMedia

Gambling.com Group (GAMB) Q4 Margin Hit With US$26.9m Loss Tests Bullish Earnings Narratives

Gambling.com Group (GAMB) closed FY 2025 with Q4 revenue of US$46.2 million and a basic EPS loss of US$0.77, alongside a trailing twelve month basic EPS loss of US$0.93 on revenue of US$165.4 million. The company has seen quarterly revenue move from US$35.3 million and basic EPS of US$0.23 in Q4 2024 to US$46.2 million with a basic EPS loss of US$0.77 in Q4 2025, while trailing twelve month revenue shifted from US$127.2 million with basic EPS of US$0.85 in Q4 2024 to US$165.4 million with a...
NasdaqCM:IPSC
NasdaqCM:IPSCBiotechs

Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives

Century Therapeutics (IPSC) just posted FY 2025 results that put revenue at US$109.2 million with basic EPS of US$0.51 for the latest half, against a trailing twelve month profile that still shows a loss, with EPS of US$0.11 and net income of US$9.6 million in the red on US$109.2 million of revenue. Over the past year, the company has reported revenue of US$1.6 million and EPS of US$0.82 in early 2024, then US$4.96 million with EPS of US$0.79 in the second half of 2024, and then the latest...
NasdaqGS:ACDC
NasdaqGS:ACDCEnergy Services

ProFrac Holding (ACDC) Losses Deepen To US$369 Million TTM Reinforcing Bearish Narratives

ProFrac Holding (ACDC) closed out FY 2025 with fourth quarter revenue of US$436.5 million and a basic EPS loss of US$0.79, alongside net income excluding extra items of a US$142.6 million loss. Over the past few quarters, the company has seen revenue move from US$600.3 million and a basic EPS loss of US$0.12 in Q1 2025 to US$403.1 million and a basic EPS loss of US$0.60 in Q3 2025. Trailing twelve month figures show revenue at US$1.9 billion and a net loss of US$369 million, setting up a...
NasdaqGS:DSP
NasdaqGS:DSPSoftware

Viant Technology (DSP) Swings To Q4 Profit As 2.4% Net Margin Tests Bullish Narratives

Viant Technology (DSP) just closed out FY 2025 with fourth quarter revenue of US$110.1 million and basic EPS of US$0.49, alongside trailing 12 month revenue of US$344.2 million and EPS of US$0.51 that sit against a net profit margin of 2.4%. Over the past few quarters the company has seen revenue move from US$70.6 million in Q1 2025 to US$110.1 million in Q4 2025, with basic EPS ranging from a loss of US$0.07 in Q1 2025 to US$0.49 in Q4 2025. This gives investors a clearer view of how the...
NasdaqGM:CCLD
NasdaqGM:CCLDHealthcare Services

CareCloud (CCLD) Profitability Turn Challenges Dilution Focus After FY 2025 Earnings

CareCloud (CCLD) has capped FY 2025 with fourth quarter revenue of US$34.4 million and basic EPS of US$0.04, alongside trailing 12 month revenue of US$120.5 million and basic EPS of US$0.10, marking a clean move away from the losses seen earlier in the period. The company has seen quarterly revenue step up from US$27.4 million in Q2 2025 to US$34.4 million in Q4 2025, while quarterly basic EPS has shifted from a loss of US$0.04 in Q1 2025 to positive readings in each subsequent quarter,...
NasdaqGS:TRIN
NasdaqGS:TRINCapital Markets

Trinity Capital Expands MedTech Exposure With US$90 Million Growth Commitments

Trinity Capital (NasdaqGS:TRIN) has recently committed growth capital to three MedTech companies: Monteris Medical, Emboline, and Neuros Medical. The financing supports commercialization of Monteris Medical's neurosurgical system, Emboline's heart procedure protection platform, and Neuros Medical's non opioid pain treatment device. These back to back commitments expand Trinity Capital's exposure to advanced medical technologies within its venture lending portfolio. Trinity Capital focuses...
NasdaqGS:VYGR
NasdaqGS:VYGRBiotechs

Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?

Voyager Therapeutics, Inc. recently reported fourth-quarter 2025 results showing a net loss of US$27.43 million, improving from US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million in 2024. Although Voyager reduced its quarterly loss per share, the much larger full-year loss highlights the cost intensity of advancing its neurological disease pipeline. We’ll now examine how Voyager’s improved quarterly loss but much larger...
NYSE:ZWS
NYSE:ZWSBuilding

Zurn Elkay Sets Records As Investors Weigh Valuation And Cash Returns

Zurn Elkay Water Solutions (NYSE:ZWS) reported record annual performance with double digit core sales growth. The company highlighted improved operating margins over the year. Management announced a substantial increase in its dividend. The company also disclosed a significant share repurchase program. Zurn Elkay Water Solutions focuses on water management products and systems, an area that sits at the intersection of infrastructure, building construction, and resource efficiency. With...
NasdaqGS:DMRC
NasdaqGS:DMRCSoftware

Digimarc (DMRC) Q4 Loss Improvement Tests Bullish Profitability Narrative

Digimarc (DMRC) has just posted its FY 2025 numbers, with Q4 revenue of US$8.9 million, a basic EPS loss of US$0.19, and net income excluding extra items showing a loss of US$4.2 million, setting the tone for how investors will read the full year. Over recent quarters, the company has seen revenue move between US$7.6 million and US$9.4 million while quarterly EPS losses ranged from US$0.19 to US$0.55, giving a clear picture of a business that is still loss making but working through its cost...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

Is It Time To Reconsider BioNTech (BNTX) After Its Recent Share Price Weakness?

If you are wondering whether BioNTech's current share price lines up with its long term potential, starting with a clear look at valuation can help you frame that question more calmly. BioNTech's shares recently closed at US$90.10, with returns of 11.6% decline over the past week, 17.3% decline over the last month, and 6.8% decline year to date, alongside 7.6% decline over 1 year, 31.7% decline over 3 years, and 12.2% decline over 5 years, which hints that the market's view on risk and...
NasdaqCM:MNTK
NasdaqCM:MNTKRenewable Energy

Montauk Renewables (MNTK) Margin Compression To 1% Tests Bullish Growth Narratives

Montauk Renewables (MNTK) closed out FY 2025 with Q4 revenue of US$43.4 million and basic EPS of US$0.02 on net income of US$2.5 million, setting the tone for a year where reported earnings and margins were under close watch. The company has seen quarterly revenue move from US$27.7 million and basic EPS of US$0.06 in Q4 2024 to a mix of losses and profits through 2025, including Q2 revenue of US$45.1 million with a loss of US$5.5 million and basic EPS of US$0.04, before landing on US$45.3...
NYSE:VEL
NYSE:VELDiversified Financial

Velocity Financial (VEL) Net Margin Surge Tests Bearish Cash Flow Concerns

Velocity Financial FY 2025 results in focus Velocity Financial (VEL) has wrapped up FY 2025 with fourth quarter total revenue of US$57.1 million and basic EPS of US$0.89, setting the tone for how investors will read the full year. The company has seen quarterly revenue move from US$84.9 million in Q4 2024 to US$57.1 million in Q4 2025, while basic EPS shifted from US$0.62 to US$0.89 over the same period, and on a trailing twelve month basis EPS stands at US$2.81 on revenue of US$183.5...
NYSE:ODC
NYSE:ODCHousehold Products

Oil Dri Corporation Of America Q2 Margin Strength Reinforces Bullish EPS Stability Narrative

Oil-Dri Corporation of America (ODC) has just posted Q2 2026 results with revenue of US$117.7 million and basic EPS of US$0.87, alongside trailing twelve month EPS of US$3.62 on revenue of US$478.9 million. Over recent quarters the company has seen revenue move between US$116.9 million and US$127.9 million, while quarterly EPS has ranged from US$0.80 to US$1.13. This sets up a picture of steady top line and earnings performance that now sits on the back of 15.6% earnings growth over the past...
NasdaqGS:SNBR
NasdaqGS:SNBRSpecialty Retail

Sleep Number (SNBR) Loss Deepens To US$2.55 EPS Challenging Turnaround Narratives

Sleep Number (SNBR) has capped FY 2025 with fourth quarter revenue of US$347.4 million and a basic EPS loss of US$2.55, as net income excluding extra items came in at a loss of US$58.5 million. The company has seen quarterly revenue move from US$393.3 million in Q1 2025 to US$327.9 million in Q2, US$342.9 million in Q3 and US$347.4 million in Q4, alongside a widening basic EPS loss over the same stretch. For investors, that mix of steady sales levels and deeper losses keeps the focus firmly...
NasdaqGM:FEIM
NasdaqGM:FEIMElectronic

Frequency Electronics (FEIM) Non Cash Earnings Risk Challenges Bullish Margin Narrative

Frequency Electronics (FEIM) has just posted Q3 2026 results with revenue of US$16.9 million, basic EPS of US$0.16 and net income of US$1.6 million. This comes in a year where trailing 12 month revenue sits at US$67.8 million and EPS at US$0.74. Over recent quarters the company has seen revenue move from US$18.9 million in Q3 2025 to US$19.0 million in Q4 2025, then US$13.8 million, US$17.1 million and now US$16.9 million. Basic EPS shifted from US$1.60 to US$0.33, US$0.07, US$0.18 and...
NasdaqCM:QTTB
NasdaqCM:QTTBBiotechs

Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative

Q32 Bio (QTTB) has just posted its FY 2025 numbers, reporting fourth quarter revenue of US$53.7 million and basic EPS of US$4.60, alongside trailing 12 month basic EPS of US$2.42 and net income of US$29.8 million. The company’s quarterly revenue has moved from US$0 and a basic EPS loss of US$1.16 in Q4 2024 to US$53.7 million and US$4.60 in Q4 2025. Interim 2025 quarters showed no revenue and basic EPS losses between US$0.60 and US$0.90, so investors will likely focus on how durable these...
NasdaqGM:FUTU
NasdaqGM:FUTUCapital Markets

Futu Holdings (NasdaqGM:FUTU) Margin Surge To 51.7% Tests Skeptical Narratives

Futu Holdings (NasdaqGM:FUTU) has capped FY 2025 with fourth quarter revenue of HK$6.0b and basic EPS of HK$24.31, set against trailing twelve month EPS of HK$81.39 on revenue of HK$21.1b and year over year earnings growth of 120.7%. Over recent periods the company has seen quarterly revenue move from HK$3.9b and EPS of HK$13.54 in Q4 2024 to HK$6.0b and EPS of HK$24.31 in Q4 2025, while trailing net profit margin sits at 51.7% compared with 43.8% in the prior year. For investors, this...
NYSE:IDT
NYSE:IDTTelecom

IDT (IDT) Q2 2026 EPS Stability Tests Bullish Faster Growth Narrative

IDT (IDT) has just posted Q2 2026 numbers with total revenue of US$320.5 million and basic EPS of US$0.84, alongside net income excluding extra items of US$20.9 million. This puts fresh detail around its earnings profile. The company has seen quarterly revenue move between US$301.9 million and US$322.8 million over the last six reported periods, while basic EPS has ranged from US$0.68 to US$0.89. This gives investors a clearer view of how sales and per share profits have been tracking into...
NasdaqGM:AMTX
NasdaqGM:AMTXOil and Gas

Aemetis (AMTX) Q4 Loss Narrows To US$0.08 EPS As Bulls Reassess Profitability Story

Aemetis (AMTX) has wrapped up FY 2025 with Q4 revenue of US$53.7 million and a basic EPS loss of US$0.08, alongside trailing 12 month revenue of US$197.6 million and a cumulative net loss of US$77.0 million. Over recent quarters, the company has seen quarterly revenue move between US$42.9 million and US$59.2 million, while basic EPS losses ranged from US$0.47 to US$0.08. This latest print keeps the focus squarely on how quickly margins can tighten up from here. See our full analysis for...
NasdaqGM:OLLI
NasdaqGM:OLLIMultiline Retail

Ollie’s Bargain Outlet (OLLI) Margin Slippage Tests Bullish Growth Narrative After FY 2026 Results

Ollie's Bargain Outlet Holdings (OLLI) just wrapped up FY 2026 with fourth quarter revenue of US$779.3 million and basic EPS of US$1.40, alongside net income of US$85.6 million, while trailing twelve month revenue came in at about US$2.6 billion with basic EPS of US$3.92. Over recent quarters the company has seen quarterly revenue move from US$517.4 million in Q3 FY 2025 to US$613.6 million in Q3 FY 2026 and from US$667.1 million in Q4 FY 2025 to US$779.3 million in Q4 FY 2026. EPS shifted...
NasdaqCM:VRCA
NasdaqCM:VRCAPharmaceuticals

Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability

Verrica Pharmaceuticals (VRCA) just closed out FY 2025 with Q4 revenue of US$5.1 million and a basic EPS loss of US$0.57, alongside trailing 12 month revenue of US$35.6 million and a basic EPS loss of US$1.68. Over the past few quarters, the company has seen revenue move from US$3.4 million in Q1 2025 to US$12.7 million in Q2 and US$14.3 million in Q3, while quarterly basic EPS has ranged from a loss of US$1.03 in Q1 to a small profit of US$0.02 in Q2 and a near breakeven loss of US$0.03 in...
NasdaqGM:MDB
NasdaqGM:MDBIT

MongoDB (MDB) Turns Quarterly EPS Positive Challenging Bearish Profitability Narratives

MongoDB (MDB) has just wrapped up FY 2026 with Q4 revenue of US$695.1 million and basic EPS of US$0.19, alongside trailing 12 month revenue of US$2.5 billion and a trailing basic EPS loss of US$0.88. Over recent quarters the company has seen revenue move from US$549.0 million in Q1 FY 2026 to US$695.1 million in Q4, while quarterly basic EPS has ranged from a loss of US$0.58 in Q2 to a profit of US$0.19 in Q4. This sets up a results season where investors are likely to focus on how improving...
NasdaqCM:SUNS
NasdaqCM:SUNSMortgage REITs

Sunrise Realty Trust (SUNS) Earnings Growth Story Tests Bearish Cash Coverage Concerns

Sunrise Realty Trust (SUNS) has just wrapped up FY 2025 with fourth quarter revenue of US$3.6 million and basic EPS of US$0.12, alongside trailing twelve month EPS of US$0.93 on revenue of US$19.5 million and year over year earnings growth of 73.2%. Over the past year, the company has seen quarterly revenue range from US$3.6 million to US$6.3 million, with basic EPS moving between US$0.12 and US$0.30. Trailing twelve month figures indicate that analysts are currently forecasting earnings...